INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date:	**Monday, May 18, 2026**
Time:	10:00 am Central Time
Location:	Zoom Teleconference
Institution:	Northwestern University, Chicago, IL
Principal Investigator:	**Alan Zhou, MD**
Protocol:	Cabaletta Bio Inc., **CAB-101**
NCT Number:	NCT04422912
Meeting Type:	Continuing Review of Protocol and Site
Title:	A phase 1/2, open-label, safety and dosing study of autologous CAR T cells (desmoglein 3 chimeric autoantibody receptor T cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T cells [CABA-201]) in subjects with active, pemphigus vulgaris

1. Call to order:

The Meeting was called to order at 10:14 am Central Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Six voting members were present, including two local members unaffiliated with the institution and the Institution's Biosafety Officer. Also present were five Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 6 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for DSG3-CAART and CABA-201 since they consist of primary human cells modified by a recombinant lentiviral vector. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of DSG3-CAART and CABA-201 locally**, provided that other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6 NO: 0 ABSTAIN: 0

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Point of Discussion:

1. The Biosafety Officer confirmed that the yellow chemotherapy containers shown in the Olson Pavilion Photos document are not typically used for biohazardous waste generated in IBC-reviewed studies and will verify with Olson Pavilion staff that such waste is not disposed of in these containers.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Biosafety Officer.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6 NO: 0 ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 10:18 am Central Time.

15. Post-meeting notes: None.

Documents reviewed:

Agenda
Protocol, Version 10.0, dated 09-30-2025
CABA-201, Investigator's Brochure, Edition 2.0, dated 07-24-2025
DSG3-CAART, Investigator's Brochure, Edition 4, dated 03-04-2024
CABA-201, Drug Product Manual, Version 8.0, dated 11-30-2025
Leukapheresis and DSG3-CAART Drug Product Manual, Version 7.0, received 01-05-2023
Research Modification Evaluation, Protocol, Version 9.0
Research Modification Evaluation, Protocol, Version 10.0
Research Modification Evaluation, Investigator's Brochure, Edition 2.0
Research Modification Evaluation, Investigator's Brochure, Edition 4
Research Modification Evaluation, Leukapheresis and Drug Product Manual, Version 6.0
Research Modification Evaluation, Drug Product Manual, Version 7.0
Research Modification Evaluation, Drug Product Manual, Version 8.0
Biological Risk Assessment and Summary, updated 03-13-2026
Site Map, Olson, 1st Floor, dated 01-23-2026
Site Map, Olson, 7th Floor, MCCT, Room 7-424, dated 02-27-2025
Site Map, Olson, 7th Floor, MCCT, Room 7-613, dated 02-19-2024
Site Map, Prentice, 16th Floor, dated 04-12-2024
Site Map, Feinberg and Olson Loading Docks, received 10-16-2018
Site Inspection Checklist, Cell Therapies, expires 03-05-2027, updated 02-20-2026
Photos, Prentice Hospital, dated 04-25-2025
Photos, Olson Pavilion, MCCT, dated 06-05-2025
Photos, Olson Pavilion, Dosing, dated 05-01-2025
Photos, Feinberg and Olson Loading Dock, dated 03-25-2026
Biohazard Sign, Prentice and Olson, dated 04-01-2026
Biohazard Sign, Olson MCCT, dated 02-20-2026
Biological Safety Cabinet Certifications, Olson MCCT, expires 09-2026
SOP, Biosafety for Genetically Modified Human Cells, dated 03-17-2025
SOP Addendum, Biosafety for Autologous Cells, dated 02-20-2026
Training, Shipping Certification, expires 06-05-2027
CRRF, dated 03-04-2026
Prior Meeting Minutes, Continuing, dated 06-04-2025